WO2002002597A3 - Peptide extended glycosylated polypeptides - Google Patents

Peptide extended glycosylated polypeptides Download PDF

Info

Publication number
WO2002002597A3
WO2002002597A3 PCT/DK2001/000459 DK0100459W WO0202597A3 WO 2002002597 A3 WO2002002597 A3 WO 2002002597A3 DK 0100459 W DK0100459 W DK 0100459W WO 0202597 A3 WO0202597 A3 WO 0202597A3
Authority
WO
WIPO (PCT)
Prior art keywords
glycosylated polypeptides
polypeptide
interest
peptide extended
peptide
Prior art date
Application number
PCT/DK2001/000459
Other languages
French (fr)
Other versions
WO2002002597A2 (en
Inventor
Jens Sigurd Okkels
Anne Dam Jensen
Den Hazel Bart Van
Original Assignee
Maxygen Aps
Maxygen Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2000/000743 external-priority patent/WO2001049830A2/en
Priority claimed from PCT/DK2001/000090 external-priority patent/WO2001058493A1/en
Application filed by Maxygen Aps, Maxygen Holdings Ltd filed Critical Maxygen Aps
Priority to AU2001267337A priority Critical patent/AU2001267337A1/en
Priority to CA002412882A priority patent/CA2412882A1/en
Priority to JP2002507849A priority patent/JP2004504016A/en
Priority to EP01944987A priority patent/EP1299535A2/en
Publication of WO2002002597A2 publication Critical patent/WO2002002597A2/en
Publication of WO2002002597A3 publication Critical patent/WO2002002597A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01003—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01001—Alpha-amylase (3.2.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01015—Polygalacturonase (3.2.1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y602/00—Ligases forming carbon-sulfur bonds (6.2)
    • C12Y602/01—Acid-Thiol Ligases (6.2.1)
    • C12Y602/01003—Long-chain-fatty-acid-CoA ligase (6.2.1.3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Glycosylated polypeptides comprising the primary structure NH2-X-Pp-COOH wherein X is a peptide addition comprising or contributing to a glycosylation site, and Pp is a polypeptide of interest or comprising the primary structure NH2-Px-X-Py-COOH, wherein Px is an N-terminal part of a polypeptide Pp of interest, Py is a C-terminal part of said polypeptide Pp, and X is a peptide addition comprising or contributing to a glycosylation site. The glycosylated polypeptides having improved properties as compared to the polypeptide of interest.
PCT/DK2001/000459 2000-06-30 2001-06-29 Peptide extended glycosylated polypeptides WO2002002597A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001267337A AU2001267337A1 (en) 2000-06-30 2001-06-29 Peptide extended glycosylated polypeptides
CA002412882A CA2412882A1 (en) 2000-06-30 2001-06-29 Peptide extended glycosylated polypeptides
JP2002507849A JP2004504016A (en) 2000-06-30 2001-06-29 Peptide-extended glycosylated polypeptides
EP01944987A EP1299535A2 (en) 2000-06-30 2001-06-29 Peptide extended glycosylated polypeptides

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
DKPA200001027 2000-06-30
DKPA200001027 2000-06-30
DKPA200001092 2000-07-14
DKPA200001092 2000-07-14
DKPCT/DK00/00743 2000-12-29
PCT/DK2000/000743 WO2001049830A2 (en) 1999-12-30 2000-12-29 Improved lysosomal enzymes and lysosomal enzyme activators
PCT/DK2001/000090 WO2001058493A1 (en) 2000-02-11 2001-02-09 Conjugates of follicle stimulating hormones
DKPCT/DK01/00090 2001-02-09

Publications (2)

Publication Number Publication Date
WO2002002597A2 WO2002002597A2 (en) 2002-01-10
WO2002002597A3 true WO2002002597A3 (en) 2002-06-27

Family

ID=56290160

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2001/000459 WO2002002597A2 (en) 2000-06-30 2001-06-29 Peptide extended glycosylated polypeptides

Country Status (5)

Country Link
EP (1) EP1299535A2 (en)
JP (1) JP2004504016A (en)
AU (1) AU2001267337A1 (en)
CA (1) CA2412882A1 (en)
WO (1) WO2002002597A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101023173B (en) * 2004-03-25 2012-08-08 埃欧金生物制品公司 Modified xylanases exhibiting improved expression

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7399613B2 (en) 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
DK1578771T3 (en) 2001-10-10 2013-06-10 Novo Nordisk As Remodeling and glycoconjugation of peptides
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
DK1515986T3 (en) * 2002-06-17 2019-01-02 Chr Hansen As Improved method of producing an asparagine protease in a recombinant host organism
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US7803777B2 (en) 2003-03-14 2010-09-28 Biogenerix Ag Branched water-soluble polymers and their conjugates
EP1613261A4 (en) 2003-04-09 2011-01-26 Novo Nordisk As Intracellular formation of peptide conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
EP1624847B1 (en) 2003-05-09 2012-01-04 BioGeneriX AG Compositions and methods for the preparation of human growth hormone glycosylation mutants
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
AU2004293103C1 (en) 2003-11-24 2010-12-02 Ratiopharm Gmbh Glycopegylated erythropoietin
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
CN101072789B (en) 2004-01-08 2013-05-15 生物种属学股份公司 O-linked glycosylation of peptides
US20080305518A1 (en) 2004-05-04 2008-12-11 Novo Nordisk Healthcare A/G O-Linked Glycoforms Of Polypeptides And Method To Manufacture Them
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
MX2007008229A (en) 2005-01-10 2007-09-11 Neose Technologies Inc Glycopegylated granulocyte colony stimulating factor.
WO2006081249A2 (en) * 2005-01-25 2006-08-03 Cell Therapeutics, Inc. Conjugates of biologically active proteins having a modified in vivo half-life
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
WO2006127910A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
EP1746161A1 (en) * 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
WO2007111496A1 (en) * 2006-03-28 2007-10-04 Universiteit Utrecht Holding B.V. Improved carbohydrate recognition domains
EP2049144B8 (en) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation of peptides via o-linked glycosylation sequences
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As Methods for the purification of polypeptide conjugates
CL2007003411A1 (en) * 2006-11-28 2008-07-04 Centelion PROTEIN FUSION THAT CONSISTS IN AN FC REGION OF AN IMMUNOGLOBULIN WITH A FRAGMENT OR SOLUBLE DOMAIN OF A RECEIVER FOR FGF; POLINUCLEOTIDO THAT CODIFIES AND VECTOR AND CELL THAT UNDERSTAND IT; PHARMACEUTICAL COMPOSITION INCLUDING PROTEIN FU
JP2010523582A (en) 2007-04-03 2010-07-15 バイオジェネリクス アクチェンゲゼルシャフト Treatment method using glycoPEGylated G-CSF
MX2009013259A (en) 2007-06-12 2010-01-25 Novo Nordisk As Improved process for the production of nucleotide sugars.
PT2173890E (en) 2007-06-21 2011-05-06 Tech Universit T M Nchen Biological active proteins having increased in vivo and/or vitro stability
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
JP5769142B2 (en) * 2007-09-04 2015-08-26 独立行政法人酒類総合研究所 Method for high secretion of heterologous proteins in Pichia yeast
CN103497247A (en) 2008-02-27 2014-01-08 诺沃—诺迪斯克有限公司 Conjugated factor VIII molecules
JP2010183885A (en) * 2009-02-13 2010-08-26 Kobe Univ Method for producing protein and expression vector used therefor
EA024755B1 (en) 2010-05-21 2016-10-31 ИксЭль-ПРОТЕИН ГМБХ Biosynthetic proline/alanine random coil polypeptides and their uses
RS55405B1 (en) * 2010-11-08 2017-04-28 Amicus Therapeutics Inc Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity
EP3068891A1 (en) * 2013-11-13 2016-09-21 Aequus Biopharma Inc. Engineered glycoproteins and uses thereof
MX368656B (en) 2013-12-20 2019-10-10 Hoffmann La Roche Improved recombinant polypeptide production methods.
WO2015091130A1 (en) * 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Method for improving the recombinant production of soluble fusion polypeptides
CA2985718A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
JP6657392B2 (en) 2015-10-02 2020-03-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Bispecific anti-human CD20 / human transferrin receptor antibodies and methods of use
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
KR20190109506A (en) * 2017-01-31 2019-09-25 리젠엑스바이오 인크. Treatment of Mucopolysaccharide Type 1 with Fully-Human Glycosylated Human Alpha-L-iduroidase (IDUA)
JP2020526514A (en) 2017-07-06 2020-08-31 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Gene therapy to treat mucopolysaccharidosis type I
KR20200104852A (en) 2017-09-22 2020-09-04 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Gene therapy for the treatment of type II mucopolysaccharides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0370205A2 (en) * 1988-09-29 1990-05-30 Kyowa Hakko Kogyo Co., Ltd. Glycosylated polypeptides
WO1990007573A1 (en) * 1988-12-23 1990-07-12 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
WO1999013081A1 (en) * 1997-09-08 1999-03-18 Akzo Nobel N.V. EXPRESSION OF GONADOTROPINS IN $i(DICTYOSTELIUM)
WO1999054342A1 (en) * 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0370205A2 (en) * 1988-09-29 1990-05-30 Kyowa Hakko Kogyo Co., Ltd. Glycosylated polypeptides
WO1990007573A1 (en) * 1988-12-23 1990-07-12 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
WO1999013081A1 (en) * 1997-09-08 1999-03-18 Akzo Nobel N.V. EXPRESSION OF GONADOTROPINS IN $i(DICTYOSTELIUM)
WO1999054342A1 (en) * 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CANTOR ALAN B ET AL: "Phosphorylation of Asn-linked oligosaccharides located at novel sites on the lysosomal enzyme cathepsin D.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 32, 1992, pages 23357 - 23363, XP002173975, ISSN: 0021-9258 *
DOEBBER T W ET AL: "ENHANCED MACROPHAGE UPTAKE OF SYNTHETICALLY GLYCOSYLATED HUMAN PLACENTAL BETA GLUCO CEREBROSIDASE", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 257, no. 5, 1982, pages 2193 - 2199, XP001002183, ISSN: 0021-9258 *
FULLER MARIA ET AL: "Receptor mediated binding of two glycosylation forms of N-acetylgalactosamine-4-sulphatase.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1406, no. 3, 28 April 1998 (1998-04-28), pages 283 - 290, XP001002494, ISSN: 0006-3002 *
FURBISH F S ET AL: "UPTAKE AND DISTRIBUTION OF PLACENTAL GLUCO CEREBROSIDASE IN RAT HEPATIC CELLS AND EFFECTS OF SEQUENTIAL DEGLYCOSYLATION", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 673, no. 4, 1981, pages 425 - 434, XP001002396, ISSN: 0006-3002 *
MURRAY G J ET AL: "TARGETING OF SYNTHETICALLY GLYCOSYLATED HUMAN PLACENTAL GLUCOCEREBROSIDASE", BIOCHEMICAL MEDICINE, vol. 34, no. 2, 1985, pages 241 - 246, XP001042190, ISSN: 0006-2944 *
WARREN CHARLES E: "Glycosylation.", CURRENT OPINION IN BIOTECHNOLOGY, vol. 4, no. 5, 1993, pages 596 - 602, XP001042143, ISSN: 0958-1669 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101023173B (en) * 2004-03-25 2012-08-08 埃欧金生物制品公司 Modified xylanases exhibiting improved expression

Also Published As

Publication number Publication date
JP2004504016A (en) 2004-02-12
WO2002002597A2 (en) 2002-01-10
AU2001267337A1 (en) 2002-01-14
EP1299535A2 (en) 2003-04-09
CA2412882A1 (en) 2002-01-10

Similar Documents

Publication Publication Date Title
WO2002002597A3 (en) Peptide extended glycosylated polypeptides
CY1112228T1 (en) MODIFIED KUNITZ PROPERTY POLICY
WO2001000666A3 (en) Self-aligning peptides derived from human elastin and other fibrous proteins
WO1996017924A3 (en) Novel hedgehog-derived polypeptides
EP2253645A3 (en) Factor VIII Polypeptide
CA2155185A1 (en) Totally synthetic affinity reagents
CA2168011A1 (en) Hybrid toxin
AU4162400A (en) Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii
WO2002002621A3 (en) Mammalian secreted proteins
WO1998005685A3 (en) Self-aligning peptides derived from elastin and other fibrous proteins
WO1999003881A3 (en) Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest
WO2002006306A3 (en) SUBSTRATES AND ASSAYS FOR β-SECRETASE ACTIVITY
AU4415796A (en) Production of c-terminal amidated peptides from recombinant protein constructs
WO2004094592A3 (en) Polymer-conjugated glycosylated neublastin
CA2077590A1 (en) Recombinant dna coding for a protein with endochitinase activity
IL193310A0 (en) Antibody directed against a polypeptide that interacts with parkin and pharmaceutical compositions comprising the same
WO1999002708A8 (en) Fusion proteins comprising sequences derived from bovine if1 atpase inhibitor protein
AU8727001A (en) A novel polypeptide-tumor suppressor protein 63 and the polynucleotide encoding said polypeptide
WO2002036154A3 (en) Procollagen (iii) propeptides and related substances for treating fibrotic diseases
AU8750601A (en) A novel polypeptide, a scan zinc-finger protein subfamily protein 57 and the polynucleotide encoding the polypeptide
AU9538501A (en) A novel polypeptide-mouse transient receptor potential protein 2 (trp2)12 and the polynucleotide encoding said polypeptide
AU2001233567A1 (en) A novel polypeptide, human protein 9 of short-chain scorpion toxin and the polynucleotide encoding the polypeptide
FR2787454B1 (en) TOPOISOMERASE II INHIBITOR
AU4632801A (en) A novel polypeptide, human protein bcr 10 and the polynucleotide encoding the polypeptide
AU2002223377A1 (en) A novel polypeptide, a human cytochrome constitutive protein 45 and the polynucleotide encoding the polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001944987

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001267337

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2412882

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 54/CHENP/2003

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2001944987

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001944987

Country of ref document: EP